Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05341622 · ClinicalTrials.gov registry record · NA
Mailed FIT Outreach 2022
A NA study of Colorectal Cancer and Colon Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 5,460
- Enrollment target
- 1
- Study location
NCT05341622: Completed NA study of Colorectal Cancer and Colon Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05341622 is a NA study of Colorectal Cancer and Colon Cancer that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 5,460 participants, above the 1,530-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (257% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05341622, a NA study of Colorectal Cancer and Colon Cancer, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 5,460 participants
- Enrollment target
- 1
- Study location
Study Summary
This project aims to evaluate different approaches to increase colorectal cancer screening among primary care patients at Penn Medicine through a centralized screening outreach program. In a pragmatic trial, we will evaluate different approaches to increase response rate to mailed fecal immunochemical test (FIT) kits among eligible patients, including differentiated packaging, sending text reminders, and personalized reminders.
Primary Outcome
Percent of patients who complete FIT
Conditions Studied
Interventions
- BEHAVIORAL Text
- BEHAVIORAL Reminder
- BEHAVIORAL Differentiated Box
- BEHAVIORAL Standard Mail
- BEHAVIORAL No Text
Study Locations (1)
Pennsylvania
- Penn Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,460 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2022-12-13 |
| Phase | NA |
What the finished NCT05341622 record still lists
NCT05341622 is an interventional study that assigns participants to a tested intervention. Its 5,460 participants enrollment target places it among the larger protocols in the corpus, above the 1,530-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (257% higher).
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Text is the first listed.
NCT05341622 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05341622 about?
NCT05341622 is a clinical study titled "Mailed FIT Outreach 2022". This project aims to evaluate different approaches to increase colorectal cancer screening among primary care patients at Penn Medicine through a centralized screening outreach program. In a pragmatic trial, we will evaluate different approaches to increase response rate to mailed fecal immunochemic...
What is the current status of trial NCT05341622?
This trial is currently completed. It is a NA study. The enrollment target is 5,460 participants. The study started on 2022-05-27. Estimated completion is 2022-12-13.
What conditions does trial NCT05341622 study?
This clinical trial studies the following conditions: Colorectal Cancer, Colon Cancer.
What interventions are being tested in trial NCT05341622?
The interventions under investigation include: Text (BEHAVIORAL), Reminder (BEHAVIORAL), Differentiated Box (BEHAVIORAL), Standard Mail (BEHAVIORAL), No Text (BEHAVIORAL).
Who is sponsoring clinical trial NCT05341622?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05341622 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05341622's enrollment target sits among peer trials
5,460 16th of 381 higher than 366 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
RECRUITING · NA
-
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
RECRUITING · NA
-
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
- NCT05952557 · 5,500 participants · Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- NCT06084234 · 5,500 participants · Phase 4
National Liver Cancer Screening Trial
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI